2 completed, 2 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Kanto CML Study Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial dasatinib - Myelogenous Leukemia, Chronic, Chronic Phase | Phase 2 | Unknown | Kanto CML Study Group | 100 | 2012-11-01 | 2013-06-27 |
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myelogenous Leukemia, Chronic, Chronic Phase | Unknown | Kanto CML Study Group | 40 | 2011-07-01 | 2011-11-03 | |
| A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib dasatinib - Chronic Myeloid Leukemia | Phase 2 | Completed | Kanto CML Study Group | 21 | 2011-04-01 | 2015-09-15 |
| A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia dasatinib - Chronic Myeloid Leukemia | Phase 2 | Completed | Kanto CML Study Group | 65 | 2009-03-01 | 2015-09-15 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Chronic-Phase (3)
Dasatinib (3)
Japan (4)
Chikashi Yoshida, MD, PhD (1) · Hisashi Sakamaki, MD.PhD (1)